# Tufts Medicine account plan

> Tufts Medicine is a Boston-area nonprofit health system of four acute hospitals, home care and an ACO network, with FY2025 revenue of $2,967.3 million.

## At a glance

Tufts Medicine, Inc. is the Boston-area nonprofit parent of Tufts Medical Center, Lowell General Hospital (Circle Health), MelroseWakefield Healthcare (two acute hospitals), Tufts Medicine Care at Home, the Tufts Medicine Integrated Network and a Cayman captive insurer. In FY2025 (year to September 30, 2025) total revenue was $2,967.3 million, up from $2,639.3 million, and the loss from operations narrowed to $58.6 million from $250.7 million. Patient service revenue of $2,342.4 million came 38% from Medicare, 39% from managed care and 18% from Medicaid. The system is in a financial turnaround on a thin balance sheet, with long-term debt of $894.8 million against net assets of $190.4 million.

## Business units

- **Tufts Medical Center** (operating revenue $1,245.7 million for the nine months to June 30, 2026): The academic flagship acute care hospital in the greater Boston area, with its physician organization, a nursing home and imaging joint ventures. It is profitable, with an operating margin of 3.9% in the nine months to June 30, 2026, but its physician organization lost $68.1 million.
- **Circle Health (Lowell General Hospital)** (operating revenue $530.3 million for the nine months to June 30, 2026): General acute care hospital in Lowell, Massachusetts, with physician practices, a pharmacy and surgical and imaging joint ventures. Its operating margin fell to 2.0% from 6.0% in the nine months to June 30, 2026.
- **MelroseWakefield Healthcare** (operating revenue $188.3 million for the nine months to June 30, 2026): Two acute care hospitals north of Boston with physician practices, long-term care and real estate affiliates. It is the weak hospital: revenue fell from $220.3 million and the operating margin was -10.1% in the nine months to June 30, 2026.
- **Tufts Medicine Care at Home** (home health and hospice are 2% of patient service revenue): Home health, hospice and homemaker services in Massachusetts and southern New Hampshire.
- **Tufts Medicine Integrated Network (TMIN)** (risk-based contracts $99.4 million of other revenue in FY2025): Population-health arm running ACOs and physician networks under commercial risk contracts and Medicare shared savings programmes, with settlements shared with affiliate physicians.
- **Tufts Medicine Indemnity Company (TMEDIC)**: Cayman Islands captive insurer providing professional and general liability and stop-loss cover to the system.

## Strategic priorities

- **Financial turnaround**: The board chair says the system is entering the next phase of its financial turnaround; the FY2025 deficiency narrowed to $51.6 million from $214.0 million.
- **Throughput and clinical growth**: The CFO named access, length of stay and growth of key clinical programs as next priorities in July 2025.
- **Payer mix and ambulatory care**: Management aims to shift payer mix and expand the ambulatory setting; outpatient grew to 41% of patient service revenue in FY2025 from 38%.
- **Rebuilding the balance sheet**: The plan includes monetizing non-strategic assets; a 30-year energy-as-a-service deal on chilled water and steam infrastructure brings about $365 million at financial close in February 2026.
- **Value-based care**: The CFO wants to bend the cost curve and move to value-based care, building on TMIN's risk contracts.

## Latest results

For the nine months to June 30, 2026 (fiscal Q3 2026), the CHIA filing shows total operating revenue of $2,468.9 million against $2,278.9 million a year earlier. The system operating loss was $79.5 million, an operating margin of -3.2% against -2.2% in the prior year-to-date, and the deficit of revenue over expenses widened to $62.8 million from $47.0 million. Tufts Medical Center improved to a 3.9% margin while MelroseWakefield fell to -10.1% and Lowell General slipped to 2.0%. Cash stood at $62.1 million and long-term debt at $914.5 million at June 30, 2026, with debt service coverage of 0.56.

## Investments and deals

- **Bond refinancing**: In November 2025 the 8.50% Series E bonds and two smaller series were refinanced into Series F ($30.2 million, 5.50%) and Series G ($154.1 million).
- **Energy-as-a-service deal**: A 30-year energy-as-a-service agreement on chilled water and steam infrastructure brings about $365 million at financial close in February 2026.
- **Lab outreach sale**: Lab outreach testing was sold to Labcorp, involving 600 roles.
- **Pharmacy growth**: Specialty and retail pharmacy revenue grew to $355.3 million in FY2025 from $244.2 million.

## Challenges and risks

- **Operating losses**: The system lost $79.5 million at the operating level in the nine months to June 30, 2026, with a -3.2% margin.
- **Thin balance sheet**: Cash was $62.1 million and long-term debt to capitalization 0.92 at June 30, 2026; capex was cut to $23.6 million in FY2025 from $51.5 million.
- **Loss-making physician organizations and MelroseWakefield**: The Tufts Medical Center Physician Organization had a -22.8% margin and MelroseWakefield a -10.1% margin in the nine months to June 30, 2026.
- **Leadership transition**: CEO Mike Dandorph and CFO Andrew Devoe are stepping down; a national CFO search is under way.
- **Cost inflation and payer denials**: The CFO cited post-COVID cost inflation and payer denials, 97-99% of which are overturned on appeal; FEMA COVID grant revenue fell to $10.9 million from $57.4 million.

## What leadership says

> "we have turned the corner, and we're starting to rebuild the balance sheet" — Andrew DeVoe, Executive Vice President and CFO, Becker's CFO + Revenue Cycle Podcast, July 9, 2025

> "While important work remains ahead, we have generated significant momentum and are entering the next phase of our financial turnaround with greater focus, discipline and purpose" — Phil Lembo, Board Chair, Healthcare Dive, August 6, 2026, on the CEO and CFO stepping down

> "Our focus remains unchanged: serving our patients and communities, supporting our people, strengthening our financial position and continuing to advance Tufts Medicine's mission to empower people to live their best lives" — Phil Okala, COO and incoming CEO, Healthcare Dive, August 6, 2026


## Where a supplier can help

- **Revenue cycle and denials**: Tied to the payer-denials challenge and the turnaround priority: revenue cycle, pre-authorization and denial-management vendors, including contingency-based offers the CFO has used, address a lever management names.
- **Throughput and capacity**: Tied to the throughput priority: patient-flow, scheduling and length-of-stay tools support access and clinical program growth.
- **Ambulatory expansion**: Tied to the ambulatory care priority: outpatient facilities, digital front door and ambulatory operations partners fit the shift away from inpatient care.
- **Value-based care analytics**: Tied to the value-based care priority and TMIN's risk contracts: population-health and care-coordination analytics support shared-savings performance.
- **Cost and asset monetization**: Tied to the thin balance sheet: suppliers offering capital-light or as-a-service models, like the energy deal, match the push to monetize non-strategic assets.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Tufts Medicine, Inc. and Affiliates – Consolidated Financial Statements and Single Audit Reports, FY ended September 30, 2025](https://app.fac.gov/dissemination/report/pdf/2025-09-GSAFAC-0000405934)

Annual report · 2026-05-26

- Tufts Medicine, Inc. is the Boston-area nonprofit parent of Tufts Medical Center, Lowell General Hospital (Circle Health), MelroseWakefield Healthcare (two acute hospitals), Tufts Medicine Care at Home, the Tufts Medicine Integrated Network (TMIN) and a Cayman captive insurer (TMEDIC).
- FY2025 (year to September 30, 2025): total revenue $2,967.3 million, up from $2,639.3 million; patient service revenue $2,342.4 million; other revenue $550.2 million, of which specialty and retail pharmacy $355.3 million.
- Loss from operations narrowed to $58.6 million from $250.7 million; deficiency in revenue over expenses $51.6 million vs $214.0 million; net cash from operations turned positive at $23.5 million (FY2024: $203.9 million used).
- Payer mix of patient service revenue: Medicare 38%, managed care 39%, Medicaid 18%; inpatient 42% and outpatient 41% of patient service revenue (outpatient up from 38%).
- Thin balance sheet: cash $65.4 million, liquidity (cash plus investments) $412.1 million, long-term debt $894.8 million net of current portion, net assets $190.4 million (down from $236.8 million); capex cut to $23.6 million from $51.5 million.
- Costs: salaries and wages $1,353.4 million; purchased services fell to $431.2 million from $492.9 million while supplies and other rose to $832.4 million from $701.2 million.
- Massachusetts 1115 Medicaid Waiver added net $78.8 million (incremental funding $248.3 million less $169.4 million paid assessments); FEMA COVID grant revenue dropped to $10.9 million from $57.4 million.
- After year-end: November 2025 refinancing of the 8.50% Series E bonds and two smaller series into Series F ($30.2 million, 5.50%) and Series G ($154.1 million, 6.375-6.625%); a 30-year energy-as-a-service deal on chilled water and steam infrastructure brings about $365 million at financial close in February 2026.
- Audited by Grant Thornton (report dated December 19, 2025, unmodified); federal awards of $55.7 million, one compliance finding on student aid status after the closure of the Lawrence Memorial Hospital School of Nursing.

### [CHIA Massachusetts Hospital and Hospital System YTD Report – data through June 30, 2026 (Tufts Medicine entities)](https://www.chiamass.gov/wp-content/uploads/2026-ytd-financial-report-through-6-30-2026.xlsx)

Interim report · 2026-09-30

- Massachusetts CHIA year-to-date filing for the nine months to June 30, 2026 (fiscal Q3 2026): Tufts Medicine total operating revenue $2,468.9 million vs $2,278.9 million a year earlier.
- System operating loss $79.5 million and operating margin -3.2% (prior YTD -2.2%); total margin -2.5%; deficit of revenue over expenses $62.8 million (prior YTD $47.0 million).
- Tufts Medical Center is profitable: operating revenue $1,245.7 million (prior YTD $1,073.2 million), operating margin 3.9% (prior YTD 2.3%).
- Lowell General Hospital: operating revenue $530.3 million, operating margin 2.0%, down from 6.0%.
- MelroseWakefield Healthcare is the weak hospital: operating revenue fell to $188.3 million from $220.3 million, operating margin -10.1% (prior YTD 0.8%).
- Physician organizations lose money: Tufts Medical Center Physician Organization operating loss $68.1 million on $298.6 million revenue (-22.8%); Circle Health Physicians -19.7%.
- Balance sheet at June 30, 2026: cash $62.1 million, total net assets $131.9 million, long-term debt $914.5 million; debt service coverage 0.56 and long-term debt to capitalization 0.92.
- Context: the median Massachusetts hospital health system had an operating margin of -1.3% and only 7 of 21 systems had an operating profit.

### [Becker's CFO + Revenue Cycle Podcast: Andrew DeVoe, Executive Vice President and CFO of Tufts Medicine](https://www.beckershospitalreview.com/podcasts/uncategorized/andrew-devoe-executive-vice-president-and-cfo-of-tufts-medicine)

Executive talk · Andrew DeVoe, Executive Vice President and CFO · 2025-07-09

- Andrew DeVoe, EVP and CFO of Tufts Medicine (joined February 2024 to lead the turnaround), on the Becker's CFO + Revenue Cycle podcast, July 2025.
- Says Tufts went from a "$300,000,000 loss run rate" when he started to a monthly profit in April 2025, about fourteen months in: "we have turned the corner".
- Levers: eliminating contract labor, centralized benchmarking that cut almost 1,000 FTEs while growing, fixing the revenue cycle (pre-authorization gaps, Epic tuning).
- Collections per RVU rose from about $68 to about $84; almost $100 million of improvement on one side of the revenue cycle.
- Uses consultants on contingency deals to move fast, as he did at Penn ($400 million of extra cash collected).
- Next priorities: throughput (access, length of stay), growing key clinical programs, a payer mix shift, expanding ambulatory care, and monetizing non-strategic assets to rebuild a weak balance sheet.
- Wants to bend the cost curve and move to value-based care, citing a below-3% cost-of-care growth rate achieved at TriHealth against 6-8% in that market.
- Trends he watches: post-COVID cost inflation, payer denials (97-99% overturned on appeal), and value-based transformation.

### [Tufts Medicine CEO, CFO step down amid financial struggles (Healthcare Dive)](https://www.healthcaredive.com/news/tufts-medicine-ceo-cfo-step-down/827248/)

Report · 2026-08-06

- Healthcare Dive, August 6, 2026: Tufts Medicine CEO Mike Dandorph and CFO Andrew Devoe are stepping down.
- Dandorph, CEO since January 2020, stays through the end of fiscal 2026 (September 30); COO Phil Okala then becomes chief executive.
- Greg Kruse, vice president of strategic operations and analytics intelligence, takes over budget planning and some financial services while a national CFO search runs.
- Board chair Phil Lembo: the system is "entering the next phase of our financial turnaround with greater focus, discipline and purpose".
- Okala: priorities include "strengthening our financial position".
- Background cited: 174 layoffs in 2024 (about 1% of the workforce), 70 administrative layoffs in 2023, sale of lab outreach testing to Labcorp (600 roles), FY2025 net loss of $51.6 million vs $214 million.

## Questions about Tufts Medicine

### What is Tufts Medicine?

A Boston-area nonprofit health system that owns Tufts Medical Center, Lowell General Hospital, MelroseWakefield Healthcare, a home care and hospice business, an ACO network and a captive insurer.

### What is Tufts Medicine's revenue?

Total revenue was $2,967.3 million in FY2025 (year to September 30, 2025). Operating revenue was $2,468.9 million for the nine months to June 30, 2026.

### Who leads Tufts Medicine?

Mike Dandorph is CEO through the end of fiscal 2026, after which COO Phil Okala becomes chief executive. Phil Lembo chairs the board.

### Is Tufts Medicine profitable?

No. It reported a loss from operations of $58.6 million in FY2025 and an operating loss of $79.5 million in the nine months to June 30, 2026, though Tufts Medical Center itself is profitable.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
